The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment

C. J. Hoekstra, S. G. Stroobants, O. S. Hoekstra, J. Vansteenkiste, B. Biesma, F. J.H.M. Schramel, N. Van Zandwijk, H. Van Tinteren, E. F. Smit

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)

Abstract

Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 disease, however, proves to be difficult with current diagnostic tests. Distant metastases may become clinically overt during induction chemotherapy (IC) or shortly after, revealing the inaccuracies of current staging algorithms. A prospective study with [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in IIIA-N2 NSCLC patients was performed to assess its value in the selection of this patient group. Fifty-seven patients received a whole body FDG PET scan as part of an ongoing response monitoring trial. Results were compared with conventional staging. In 32/57 (56%) PET suggested upstaging, which was confirmed in 17/57 (30%) with a median follow-up of 16 (range 2-49) months. These results show that using the conventional staging algorithm a substantial group of patients was understaged. FDG PET improves the selection of patients suitable for CMT.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalLung Cancer
Volume39
Issue number2
DOIs
Publication statusPublished - 1 Feb 2003
Externally publishedYes

Keywords

  • [F]fluoro-2-deoxy-D-glucose
  • Combined modality treatment
  • Locally advanced NSCLC
  • Positron emission tomography

Fingerprint

Dive into the research topics of 'The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment'. Together they form a unique fingerprint.

Cite this